Status:
COMPLETED
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an add...
Eligibility Criteria
Inclusion
- Type 2 Diabetes
- Treated with oral anti-diabetic drug therapy therapy including Metformin for at least 8 weeks prior to enrolment
- HbA1c \>6.5% and \</=10%
Exclusion
- Type 1 Diabetes
- Insulin therapy within one year of enrolment
- Renal (kidney) failure or dysfunction
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
1217 Patients enrolled
Trial Details
Trial ID
NCT00660907
Start Date
March 1 2008
End Date
January 1 2013
Last Update
March 30 2015
Active Locations (76)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Buenos Aires, Argentina
2
Research Site
Caba, Argentina
3
Research Site
Capital Federal, Argentina
4
Research Site
Ciudad de Buenos Aires, Argentina